Table 2.
Clinical characteristics of patients for ELISA validation.
| Patients with COPD | Patients with COPD-PH | P -value | |
|---|---|---|---|
| (n, M, M% = 18, 18, 100%) | (n, M, M% = 28, 25, 89.28%) | ||
| Age (year) | 66.28 ± 5.81 | 66.25 ± 6.75 | 0.49 |
| Smoking (pack-year) | 28.17 ± 3.53 | 25.54 ± 3.01 | 0.58 |
| NT-pro-BNP (pg/mL) | 114.9 ± 148.50 | 478.30 ± 1,265 | 0.12 |
| FEV1/FVC (%) | 47.69 ± 2.748 | 44.72 ± 2.12 | 0.39 |
| Predicted FEV1 (%) | 41.14 ± 11.03 | 36.49 ± 9.98 | 0.15 |
| EF (%) | 71.28 ± 4.82 | 66.32 ± 8.47 | <0.05* |
| RAD (mm) | 31.06 ± 3.78 | 36.86 ± 7.276 | <0.01** |
| RVD (mm) | 20.83 ± 2.09 | 24.54 ± 6.13 | <0.01** |
| PASP (mmHg) | 30.39 ± 3.65 | 49.86 ± 11.97 | <0.01** |
M, the number of Male; M%, the percentage of Male; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; FEV1/ FVC, Tiffeneau index; predicted FEV1, predicted forced expiratory volume in 1 s; EF, ejection fraction; RVD, right ventricular diameter measured by Doppler Echocardiography, RAD, the transverse diameter of right atrium measured by Doppler Echocardiography; PASP, systolic pulmonary arterial pressure measured by Doppler Echocardiography.
*
P < 0.05 vs. COPD group,
**
P < 0.01 vs. COPD group, absolute case numbers (% of cases in group). Values are shown as n (%) or mean ± SEM.